Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Innovator versus generic ezetimibe LDL-C comparative effectiveness study
TCTR20260930004Completed
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Double-blind, single-arm trial of ezetimibe in dyslipidemia and hypercholesterolemia, sponsored by None. Primary endpoint: Reduction in LDL-C level after switching from original to generic ezetimibe. Started Jan 2023; status: completed.
02
Drugs
ezetimibe
03
Conditions
dyslipidemiahypercholesterolemia
Beyond the preview
Go deeper on TCTR20260930004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260930004.